Abstract

Multidrug-resistant Pseudomonas aeruginosa is one of the worldwide health problems involved in elevated mortality and morbidity. Therefore, it is important to find a therapeutic for this pathogen. In the present study, we have designed a chimeric vaccine against P. aeruginosa with the help of comparative proteomics and reverse vaccinology approaches. Using comparative subtractive proteomic analysis of 1,191 proteomes of P. aeruginosa, a total of twenty unique non-redundant proteomes were selected. In these proteomes, fifteen outer membrane proteins (OMPs) of P. aeruginosa were selected based on the basis of hydrophilicity, non-secretory nature, low transmembrane helix (<1), essentiality, virulence, pathway association, antigenic, and protein-protein network analysis. Reverse vaccinology approach was used to identify antigenic and immunogenic MHC class I, MHC class II and B cell epitopes present in the selected OMPs that can enhance T cell and B cell mediated immunogenicity. The selected epitopes were shortlisted based on their allergenicity, toxicity potentials, solubility, and hydrophilicity analysis. Immunogenic peptides were used to design a multi-epitope vaccine construct. Immune-modulating adjuvants and PADRE (Pan HLA-DR epitopes) sequence were added with epitopes sequence to enhance the immunogenicity. All the epitopes, adjuvants and PADRE sequence were joined by linkers. The designed vaccine constructs (VT1, VT2, VT3, and VT4) were analyzed by their physiochemical properties using different tools. Selected chimeric vaccine constructs (VT1, VT3, and VT4) were further shortlisted by their docking score with different HLA alleles. The final selected VT4 construct was docked with TLR4/MD2 complex and confirmed by molecular dynamics simulation studies. The final vaccine VT-4 construct was in-silico cloned in pET28a. Therefore, the designed construct VT4 may be studied to control the interaction of P. aeruginosa with host and infection caused by P. aeruginosa.

Highlights

  • Hospital-based surveillance studies as well as Infectious Diseases Society of America have begun to refer nosocomial pathogens as ESKAPE pathogens that include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species

  • Subtractive genomics[29,30] and reverse vaccinology[31,32] are using as a potent mechanism to filter-out antigenic and immunogenic proteins that can be used as a chimeric vaccine candidate

  • The data presented here demonstrate that stepwise prioritization of proteome using different comparative proteomics and reverse vaccinology approaches which are an effective way of rapidly reducing the unwanted number of P. aeruginosa proteins

Read more

Summary

Introduction

Hospital-based surveillance studies as well as Infectious Diseases Society of America have begun to refer nosocomial pathogens as ESKAPE pathogens that include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. Current immunization strategies target multiple OMPs as antigens because there is no risks of pathogen reverting back to its virulent form as well as there are few adverse effects as compared to live attenuated or killed whole cell vaccination. This bacterium rapidly acquired the resistance against multiple antibiotics, natural products, herbal products which caused the problems worldwide. The chimeric vaccine can be constructed and validated

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call